Overall, these observations indicate that targeting the circHIPK3/miR-1207-5p/FMNL2 and c-Myb/circHIPK3/miR-7 axes may constitute a potential therapeutic strategy for CRC. This evidence concerns the gene MYB and colorectal carcinoma.